中文Vientiane, Laos - July 04, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative treatments for cancer, announced today that four products has been approved by the Lao Ministry of Health.
Approved drugs are:
Osimertinib: Sold under the brand name OYSIENDX. Osimertinib is a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is currently the first-line treatment for advanced lung cancer with EGFR sensitive mutations and T790M mutation lung cancer after first- or second-generation TKI treatment. The preferred drug for second-line treatment, the median progression-free survival (PFS) time reaches 18.9 months and 10.1 months respectively, bringing hope to some patients with advanced lung cancer.
Mobocertinib: Sold under the brand name MOBDX. The U.S. FDA granted accelerated approval to mobotinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon20 ins whose disease progressed during or after platinum-based chemotherapy.
Avatrombopag: sold under the brand name AVATODX, is the world's first FDA-approved oral thrombopoietin receptor agonist (TPO-RA) for CLD-associated thrombocytopenia. As the first drug for the treatment of chronic liver disease (CLD)-related thrombocytopenia, it has introduced a world-leading "strong and durable, safe and convenient" new diagnosis and treatment plan for patients with chronic liver disease (CLD)-related thrombocytopenia.
Acalabrutinib: Sold under the brand name AKADX, it is a targeted therapy drug. Targeted therapy is the result of years of research aimed at understanding the differences between cancer cells and normal cells. Targeted therapy attacks cancer cells while minimizing damage to normal cells and reducing side effects.
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.